Table 1.
Characteristic | No. (%) of Patients |
---|---|
Sex | |
Male | 52 (63) |
Female | 31 (37) |
Age, years | |
Median 62 y (25–80 y) | |
<50 | 13 (16) |
≥50 | 70 (84) |
NE | |
Pathological | 38 (46) |
Normal | 45 (54) |
KPS | |
<70% | 12 (14) |
≥70% | 71 (86) |
Epilepsy | |
Yes | 34 (41) |
Not | 49 (59) |
GBM sitea | |
Frontal lobe | 18 (22) |
Fronto-temporal lobe | 7 (8) |
Temporal-occipital lobe | 3 (4) |
Fronto-parietal lobe | 6 (7) |
Temporal lobe | 24 (29) |
Temporo-parietal lobe | 7 (8) |
Parietal lobe | 7 (8) |
Parieto-occipital lobe | 4 (5) |
Corpo callosum, talamic | 3 (4) |
Multifocal | 4 (5) |
Extent of surgery | |
Residual >20% | 29 (35) |
Residual <20% | 5 (6) |
Total | 49 (59) |
RPA Class | |
III | 3 (4) |
IV | 47 (57) |
V | 18 (22) |
VI | 15 (17) |
Stupp Protocol | |
Yes | 47 (57) |
No/Palliative care | 36 (43) |
MGMT | |
Methylated | 14 (36) |
Unmethylated | 30 (17) |
Not available | 39 (47) |
Abbreviations: GBM, glioblastoma multiforme; KPS, Karnofsky performance status; MGMT, O6-methylguanine- methyltransferase enzyme; NE, neurological examination; RPA, Recursive Partitioning Analysis.
aCorrelation between GBM localization and epilepsy at the χ2 test, P .021.